Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 184 participants.

Also called NCT02941367

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 184 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02941367
Other papers using this trial's data
  • Safety of lixisenatide plus basal insulin treatment regimen in Indian people with type 2 diabetes mellitus during Ramadan fast: A post hoc analysis of the LixiRam randomized trial Diabetes research and clinical practice, 2020-05 DOI, PubMed 32302665

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
India, Israel, Kuwait, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02941367. Randomized; no masking; primary purpose treatment. Start 2017-02-23 (actual); primary completion 2017-08-04 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan
Acronym
LixiRam
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Lixisenatide (AVE0010)
Intervention (Drug)
Sulfonylurea
Intervention (Drug)
metformin
Intervention (Drug)
basal insulin
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct02941367
Content hash
aaf98583b9bcf4f73af4cc37798f33c0526fb61dc79279178d9177d2bca4a82d